Discussing the EV-103 Cohort K study, which resulted in the FDA approval of Enfortumab Vedotin + Pembrolizumab FDA Approval in the Cisplatin ineligible advanced urothelial carcinoma patients. In discussion with the lead author, Dr. Jonathan Rosenberg – Chief of Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center.
![FDA Approval of Enfortumab + Pembrolizumab](https://oncbrothers.com/wp-content/uploads/2023/07/Screenshot-2023-07-31-184810-1200x492.png)